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The Role of Tropomyosin in 
Cardiac Function and Disease
David F. Wieczorek
Abstract
Phosphorylation of cardiac sarcomeric proteins plays a major role in the regula-
tion of physiological performance of the heart. Tropomyosin, an essential thin fila-
ment protein, regulates muscle contraction and relaxation through its interactions 
with actin, myosin, and the troponin complex. Studies demonstrate that changes 
in tropomyosin phosphorylation occur both postpartum and in response to cardiac 
hypertrophy and heart failure. To address the significance of tropomyosin phos-
phorylation on cardiac function, we conducted experiments to ascertain the effects 
of constitutive pseudophosphorylation, dephosphorylation, and dephosphorylation 
in hypertrophic cardiomyopathic hearts. Recent work demonstrates that pseudo-
phosphorylation of tropomyosin results in dilated cardiomyopathy. Tropomyosin 
dephosphorylation results in a compensated or physiological cardiac hypertrophic 
phenotype. In addition, we demonstrated that tropomyosin dephosphorylation 
phenotypically rescues hearts undergoing cardiac hypertrophy. In summary, these 
studies collectively demonstrate a significant biological and physiological role for 
tropomyosin phosphorylation under both normal and cardiomyopathic conditions.
Keywords: tropomyosin, contractile protein phosphorylation, physiological 
hypertrophy, heart disease
1. Introduction
The cardiovascular system plays an essential role in the viability of all vertebrate 
organisms by supplying oxygen and nutrients to the cells and tissues of the body 
and removing carbon dioxide. Because the demands of the body change rapidly, 
the heart must be able to respond and adapt to ever-changing environments that it 
confronts on a daily basis, such as developmental changes, physiological pressures, 
and chemical stimuli. One mechanism that is utilized by the heart is employing 
multiple contractile protein isoforms that can alter cardiac function under different 
conditions. Myosin heavy and light chains, skeletal and cardiac actin, the troponin 
complex, and α- and β-tropomyosin are contractile proteins that have multiple 
isoforms that are normally differentially expressed in the developing or adult 
heart. However, these changes in isoform expression during development usually 
occur over a time period of days to weeks. To respond to more rapidly changing 
conditions, such as acute stress, a faster and reversible mechanism is warranted to 
alter protein function, such as protein phosphorylation. The focus of this article is 
to address the role tropomyosin phosphorylation plays in cardiac function and to 
illustrate what we have learned about sarcomeric performance from these studies.
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2. Tropomyosin expression and phosphorylation in the heart
Tropomyosin (Tpm) is encoded by four distinct genes, with each gene generat-
ing multiple isoforms through alternative splicing [1, 2]. These isoforms exhibit 
developmental and tissue-/cell-specific regulation by the production of striated and 
smooth muscle, brain, and cytoskeletal/nonmuscle mRNAs and proteins. There 
are three major striated muscle Tpm isoforms, referred to here as α-Tpm, β-Tpm, 
and γ-Tpm. The associated striated muscle Tpm proteins exhibit an alpha-helical 
coiled-coil dimer structure that exists as either homo- or heterodimers. Cummins 
and Perry [3] and Izumo et al. [4] found that the myocardium of adult small 
mammals expresses striated muscle α-Tpm, while fetal heart tissue expresses both 
α- and β-Tpm isoforms. In a more detailed analysis, we determined that the striated 
muscle-specific β-Tpm isoform is constitutively expressed in murine embryoid bod-
ies during embryogenesis in utero [5]. However, the striated muscle α-Tpm isoform 
is not present until the day 5 embryoid body and the day 7.5 post coitus embryo. 
Further analyses show that both the striated muscle α- and β-Tpm isoforms are 
expressed during cardiogenesis (day 11–19 embryonic hearts), with the α-Tpm tran-
scripts becoming the predominant Tpm isoform in the adult mouse heart [5]. The 
ratio of striated muscle α- to β-Tpm mRNAs changes from 5:1 to 60:1 as the mouse 
myocardium transitions from an embryonic to an adult state. γ-Tpm is expressed 
in slow-twitch skeletal musculature, but is not found in the heart. In addition, a 
cardiac specific α-Tpm isoform, called Tpm1κ, is expressed in humans and other 
select organisms [6, 7].
Tpm, an α-helical coiled-coil protein dimer, plays an essential role in the regu-
lation of contraction and relaxation in the thin filament of the sarcomere. Tpm 
regulates contractile activity through its interactions with actin and the troponin 
complex in the sarcomere. During muscle relaxation when cytoplasmic levels of 
calcium are low, Tpm blocks the myosin-binding site on the filamentous striated 
muscle actin. Upon stimulation, cytosolic calcium concentrations increase and 
bind to troponin C which, through its association with troponin T and I, mediates 
a conformational change in the Tpm position on actin. This repositioning of Tpm 
on actin exposes the myosin-binding site. Myosin binds to actin and triggers muscle 
contractile activity until the stimulation ceases, and calcium is resequestered into 
the sarcoplasmic reticulum.
Phosphorylation is a major regulator of cardiac function by affecting numerous 
membrane, cytoplasmic, and sarcomeric proteins. Alterations in the phosphoryla-
tion of contractile proteins, such as troponin I, myosin-binding protein C, and the 
regulatory light chains can affect myofilament calcium sensitivity and to physiologi-
cally regulate cardiac function [8–12]. Previous investigations established that Tpm 
is phosphorylated at serine 283, the penultimate amino acid of the protein (Figures 1 
and 2) [13–17].
Figure 1. 
Diagram of the HCM Tpm180 mutation and the Tpm phosphorylation site. Diagramed in the figure is α-Tpm 
and the regions where TnT binds Tpm. The number above the Tpm molecule represents the amino acid residues 
where the hypertrophic cardiomyopathy (HCM) mutation is found and the position of the serine amino acid 
that is phosphorylated in Tpm.
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This region of Tpm, specifically the carboxyl terminus, plays a critical role in its 
interaction with actin and troponin T (TnT), and its ability to facilitate polymeriza-
tion with other Tpm molecules in a head-to-tail fashion [19–21]. Tpm phosphoryla-
tion may play a role in increasing the actin-activated myosin S1 ATPase activity, and 
increase the bond duration between actin-myosin interactions [22, 23]. Thus, phos-
phorylated Tpm may have an allosteric effect on actin to modify the actin-myosin 
interaction between the blocked, closed, and open states [24, 25]. Furthermore, the 
Tpm carboxyl region interacts with TnT, and work by our laboratory demonstrates 
this region dramatically affects cardiac function by regulating rates of contraction 
and relaxation, in addition to influencing myofilament calcium sensitivity [26]. The 
specific role that Tpm phosphorylation plays in influencing the physiological role 
of the carboxyl terminus and its interactions with the other contractile proteins in 
determining cardiac function was the subject of our investigations [14, 27, 28], and 
is being addressed in our current work [29].
The serine residue at amino acid 283 is the phosphorylation site found in the 
three striated muscle Tpm isoforms. With respect to Tpm phosphorylation, this 
posttranslational process is developmentally regulated, with 60–70% phosphory-
lated α-Tpm being present in the murine heart during fetal and newborn stages, 
and a developmental decrease to approximately 30% α-Tpm phosphorylation in the 
adult mouse heart [28]. Interestingly, within the heart, there is differential Tpm 
phosphorylation among the four cardiac chambers, with atria exhibiting the highest 
level of phosphorylation ([30], and Sheikh and Wieczorek unpub. result). We have 
also found Tpm phosphorylation in human hearts; we determined Tpm is phos-
phorylated in substantial amounts in both the left and right ventricles, in addition 
to the interventricular septum. The amount of Tpm phosphorylation that occurs in 
human atria is currently unknown.
Several different kinases are implicated in the phosphorylation of striated 
muscle Tpm at the serine 283 amino acid. Investigators have identified tropomyosin 
kinase, protein kinase A, and protein kinase Cζ as playing potential roles in this 
process [15, 17, 31–33]. Also, a kinase isolated from chicken embryos has been 
found to phosphorylate Tpm [32]. Recent studies by our laboratory determined 
Figure 2. 
Model of the Ser283 residues at the C-terminus of tropomyosin. C-terminal Tpm α-1 peptides are shown in 
dark red and green, troponin T is purple, and the N-terminal Tpm α-1 peptide is shown in gray (adapted from 
PDB code 2Z5H [18]). Ser283 residues are shown as yellow sticks, highlighted by the black oval. Residues in the 
Tpm α-1 N-terminal peptide that are positively (blue) or negatively (red) charged are highlighted. Of the two 
C-terminal Tpm α-1 peptides in the 2Z5H structure, one shows electron density straight through Ser283 (green 
helix), while the other only shows density through Met281 (dark red helix). Thus, the six C-terminal residues 
from the complete helix were superimposed on the incomplete helix to illustrate the putative position of Ser283 
on this chain (tan extension). Note that in this model, only 1 TnT molecule is present.
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that casein kinase 2 can phosphorylate the striated muscle α-Tpm isoform, and this 
phosphorylation is specific for the S283 amino acid residue [29]. It is possible that 
dependent upon conditions (i.e., fetal vs. adult stages, skeletal vs. cardiac muscle, 
normal physiologic conditions vs. hypertrophic stress vs. physiological stress) that 
different kinases are activated to phosphorylate striated muscle Tpm in a myofiber-
specific manner at different developmental stages and/or physiological conditions. 
Determining this relationship between specific kinases and their phosphorylation 
activity on Tpm is an area for future exploration.
3. Constitutive phosphorylation of Tpm leads to dilated  
cardiomyopathy
Previous investigations addressed the functional effect of phosphorylated Tpm 
using in vitro biochemical systems. As mentioned, biochemical assays, myofiber 
analyses, and molecular simulations indicate Tpm phosphorylation enhances 
the stiffness of the head-to-tail Tpm overlap region and its binding to TnT, while 
decreasing myofibril relaxation without significantly affecting cooperativity or 
altering activation kinetics [11, 22, 34]. Recently, we embarked on studies to address 
the physiological importance of Tpm phosphorylation in the heart using an in vivo 
model system [29]. The system we employed involved generating transgenic (TG) 
mice that expressed a phosphorylation mimetic specifically in the heart. Using the 
α-myosin heavy chain promoter (α-MHC), an α-Tpm cDNA construct that incorpo-
rated an aspartic acid residue replacement of serine at amino acid 283 (S283D) was 
expressed specifically in murine cardiomyocytes (Figure 3). Usage of an aspartic 
acid residue, which is negatively charged, mimics the negative charges found with 
phosphorylated amino acids, thus representing a pseudophosphorylation event.
Dilated cardiomyopathy (DCM) is a cause of significant morbidity and mortal-
ity in human patients. DCM is characterized by chamber dilation, systolic and/
or diastolic dysfunction, arrhythmias, and sudden cardiac death. Results show 
that Tpm S283D mice that express high levels of the transgenic protein exhibit a 
severe dilated cardiomyopathy within 2 weeks postpartum (Figure 4). Similar to 
other Tpm transgenic mice, expression of the exogenous Tpm transgene leads to a 
reciprocal decrease in the endogenous Tpm protein, thereby demonstrating a trans-
lational feedback mechanism that regulates the total amount of Tpm protein in the 
cardiomyocytes [35]. This regulatory mechanism controlling Tpm protein levels is 
also operative when one allele of the Tpm gene is ablated [36]. In Tpm S283D mice, 
there is also a significant increase in the heart:body weight ratio, and these mice 
usually die by 1 month of age. A morphological and histological analysis of the Tpm 
S283D mice that express moderate levels of the transgene shows the hearts display a 
mild cardiomyocyte hypertrophy with limited fibrosis [29]. This moderate pheno-
type does not appear to progress to a more severe condition, even after 1 year. In 
addition, there are no significant differences in the heart:body weight ratio at either 
Figure 3. 
Structure of a DNA transgenic construct showing the positions of the amino acid changes in the generation of 
Tpm mouse models. The striated muscle α-Tpm cDNA was ligated to the α-MHC promoter and the human 
growth hormone 3’ UTR. Various changes in the Tpm amino acid sequences are indicated above the construct: 
the HCM mutation glutamic acid (E) is substituted for glycine (G); the phosphor-mimetic aspartic acid (D) is 
substituted for serine (S); the nonphosphorylatable alanine (A) is substituted for serine (S).
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3 or 6 months of age. Interestingly, these hearts do display significant physiological 
differences that are similar to those exhibited by dilated cardiomyopathic hearts.
To understand the functional significance of Tpm phosphorylation, we con-
ducted various physiological measurements of cardiac and myofilament function. 
The work-performing heart model was used to obtain an ex vivo assessment of 
cardiac performance. Measurements were obtained to assess both contractile and 
relaxation parameters in the few high-expression mice that survived to 6 months of 
age, and in moderate expression mice; the results were similar regardless of the level 
of expression of the transgene. The values obtained show that there are no signifi-
cant differences in the rates of contraction (+dP/dt) or in the time to peak pressure 
(TPP); however, the rates of relaxation (−dP/dt) is significantly reduced, concomi-
tant with an increase in the half-time to relaxation (RT ½) (Table 1). Additional 
studies determined that the reduced relaxation performance by Tpm S283D hearts 
is maintained during maximal stimulation with isoproterenol, a β-adrenergic ago-
nist that stimulates muscle contraction and relaxation. To determine whether the 
relationship between Ca2+ concentration and force-tension development is altered 
in myofibers at the sarcomeric level in Tpm S283D hearts with the phosphomimetic 
residue, we analyzed skinned fiber bundles from the papillary muscle of moderate 
and high-expression mice. No significant changes in absolute tension or normal-
ized tension in NTG vs. TG mice are found (Table 1). Additionally, there are no 
significant differences in pCa50 or the Hill coefficient, a measure of the cooperative 
activation of the thin filament of the sarcomere.
Figure 4. 
Control and Tpm S283D mouse hearts. A. Whole hearts of control (left) and TG (right). B. H & E staining of 
NTG (left) and TG (right) cross sections. C. Measurement of heart:body weight ratio. ***P < 0.0001 NTG vs. 
TG [29].
Mouse model Maximum rate 
of contraction
Maximum 
rate of 
relaxation
Myofiber 
Ca2+ 
sensitivity
Sarcomere tension 
development
α-Tpm 100% 100% 100% 100%
α-Tpm S283D 100% ↓ 100% 100%
α-Tpm S283A 100% 100% 100% 100%
HCM α-Tpm E180G 100% ↓ ↑ ↑
HCM α-Tpm E180G/
S283A
↑ 100% 100% 100%
Table 1. 
Physiological parameters of cardiac and myofiber function in Tpm mouse models.
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We investigated potential signaling molecules that may play a role in the devel-
opment of the DCM phenotype. The ERK1/2 signaling pathway regulates a balance 
between HCM and DCM [37]. Research has determined that there is a correlation 
between activation of the ERK1/2 pathway and HCM, whereas inhibition of the 
ERK pathway results in DCM [37]. Our previous investigations found that Tpm 
54 DCM hearts have alterations in the levels of various kinases, including ERK1/2 
and phosphor ERK1/2 [38]. In the Tpm S283D hearts, we find decreased expression 
of ERK1/2, phosphorylated ERK1/2, phosphorylated RSK3, and JNK1 which are 
members of the ERK pathway and associated with DCM. Thus, our current work 
on Tpm phosphorylation demonstrates that this posttranslational process not only 
affects cardiac function but also activates various signaling pathways associated 
with physiological and cardiomyopathic processes.
4. Tpm dephosphorylation leads to compensated cardiac hypertrophy
Although previous in vitro investigations addressed the effect of Tpm phosphoryla-
tion on myofilament function, studies have not examined the functional importance 
of Tpm dephosphorylation. To investigate the in vivo effect of decreased or ablated 
Tpm phosphorylation, we substituted serine 283 with an alanine (S283A), removing 
the phosphorylation site and effectively inhibiting the ability of α-Tpm to be phos-
phorylated. Transgenic mice were generated using the cardiac-specific myosin heavy 
chain promoter coupled to the α-Tpm S283A cDNA (Figure 3) [14]. Exogenous non-
phosphorylatable Tpm protein expression ranged from 86 to 94%, with a concomitant 
reciprocal decrease in the endogenous Tpm levels. Interestingly, morphological analy-
ses on these transgenic mouse hearts show only a very mild increase in cardiomyocyte 
disarray, along with a significant increase in cardiomyocyte area. Results also show no 
changes in the heart-to-body weight ratio, most likely due to the moderate nature of 
this hypertrophy. There are also no differences in the survival of these transgenic mice.
To address the functional significance of Tpm dephosphorylation, we 
employed myofilament calcium sensitivity assays, echocardiography, and the 
work- performing heart model. Skinned fiber bundles from adult papillary muscle 
TG mice show no significant changes in absolute tension or normalized tension 
from the Tpm S283A hearts (Table 1) [14]. Additionally, there are no significant 
differences in myofiber calcium sensitivity, pCa50 value, or the Hill coefficient. 
These results demonstrate that the relationship between Ca2+ concentration and 
force-tension development is similar in control and Tpm S283A myofilaments 
at the sarcomeric level. The work-performing heart model allows an ex vivo 
functional analysis of murine cardiac physiology. To determine the physiological 
effects of decreased Tpm phosphorylation in the Tpm S283A hearts, contractile 
and relaxation parameters were determined. Results showed that there are no 
changes in contractile and relaxation parameters in TG hearts, either under 
basal conditions or when isoproterenol is administered (Table 1) [14]. To assess 
whether decreased Tpm phosphorylation levels has an effect on in vivo cardiac 
function, we performed echocardiographic analysis. No physiological changes 
in heart function between control and TG mice as shown by fractional shorting, 
cardiac output, or ejection fraction are observed. However, there are sex-specific 
differences in cardiac morphology: male TG animals show significant increases 
in left ventricular mass and left ventricular anterior and posterior wall thickness, 
thus indicating a hypertrophic phenotype without associated functional defects. 
Female TG mice do not demonstrate any altered morphological or physiological 
effects in their hearts. Differences in the development of cardiac hypertrophy 
between sexes have been reported previously [39, 40] and demonstrate the 
moderate nature of this hypertrophic phenotype.
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The lack of changes in cardiac function, myofilament cooperativity, and Ca2+ 
sensitivity, coupled with the development of compensated hypertrophy, lead to an 
investigation of possible signaling mechanisms involved in cardiac compensated or 
physiological hypertrophy. The Tpm S283A hearts exhibit no changes in common 
cardiomyopathic markers, such as β-myosin heavy chain, brain natriuretic peptide 
(BNP), and atrial natriuretic peptide (ANP) [14]. We did find that Tpm S283A hearts 
exhibit increased levels of SERCA2a protein. Total phospholamban protein expression 
is unchanged; however, phosphorylated phospholamban protein is increased. These 
alterations in Ca2+ handling proteins may be necessary to maintain normal cardiac 
function as the hearts compensate for the dephosphorylated Tpm that is incorporated 
into their myofilaments. Physiological cardiac hypertrophy is often associated with 
increased levels of SERCA2a, but without alterations in total phospholamban protein 
levels. Animals that exhibit physiological or compensated hypertrophy associated 
with exercise training appear to have cardiomyopathy marker and Ca2+ handling 
expression profiles that are similar to the Tpm S283A hearts, although the molecular 
expression profile during exercise training is not well elucidated. Collectively, our 
results demonstrate that Tpm dephosphorylation plays a role in the maintenance of a 
physiological or compensated hypertrophic phenotype. An area of future investiga-
tion would be to determine the level of Tpm phosphorylation in mouse hearts under-
going exercise training and exhibiting compensated cardiac hypertrophy.
5. Decreasing Tpm phosphorylation rescues hypertrophic 
cardiomyopathy
Mutations in cardiac contractile proteins are associated with the development 
of hypertrophic cardiomyopathy (HCM), also referred to familial hypertrophic 
cardiomyopathy (FHC). This disease is characterized by left and/or right ventricu-
lar hypertrophy, myocyte disarray, fibrosis, and cardiac arrhythmias that may lead 
to premature sudden death. At least 11 point mutations have been defined in Tpm 
that lead to HCM [41]. Work in our lab shows that the HCM Tpm mutation E180G 
in transgenic mice leads to a severe hypertrophic cardiomyopathy, similar to the 
phenotype exhibited by human patients [42, 43]. These TG mice exhibit signifi-
cantly enlarged left ventricles, left and right atria, with disorganized myocytes and 
increased fibrosis. The hearts of these mice also exhibit physiological dysfunction, 
including decreased rates of relaxation, increased myofiber Ca2+ sensitivity, and 
increased maximum tension (Table 1) [43, 44]. Previous work in our laboratory 
found that mating these Tpm E180G mice with α-/β-Tpm chimeric mice could 
“rescue” double-transgenic progeny from the HCM phenotype [45]. This rescue 
from the severe physiological and pathological consequences of the HCM mutation 
was mediated by the attenuation of myofilament Ca2+ sensitivity by exchanging 
amino acids at the carboxy terminus from the α-Tpm to β-Tpm isoform, a region of 
Tpm that interacts with troponin T. This work demonstrated that alterations in the 
calcium response mediated through contractile proteins can prevent the pathologi-
cal and physiological effects of HCM.
Our aforementioned investigations show that decreasing Tpm phosphorylation 
can lead to a compensated hypertrophic phenotype with significant increases in 
SERCA2a expression and phosphorylation of phospholamban. Since we determined 
that cardiac hypertrophy could be phenotypically rescued through modification 
of the response of the myocyte to Ca2+, we decided to further test this hypothesis. 
We generated TG mice that coexpressed the HCM α-Tpm E180G mutation with 
the α-Tpm S283A mutation in the same expression construct [27]. These double 
mutant transgenic (DMTG) mouse hearts express 50–64% exogenous Tpm protein, 
coupled with a concomitant decrease in endogenous Tpm protein; the amount of 
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Tpm phosphorylation in these double TG mice was minimal, similar to the levels 
found in the Tpm S283A mouse hearts. A detailed histological and morphological 
analysis show that the DMTG hearts exhibit a phenotype that is very similar to 
age-matched control mice with no cardiomyocyte disarray, atrial or ventricular 
enlargement, or excessive fibrosis, changes which are characteristic of the Tpm 
E180G hearts (Figure 5) [27]. Also, there were no differences in heart weight:body 
weight ratios between control and DMTG animals. The addition of the S283A amino 
acid substitution into the HCM α-Tpm E180G mice considerably extended the life 
expectancy of these DMTG mice to that of wild-type control mice.
To determine whether decreased Tpm phosphorylation could improve cardiac 
function in a model of hypertrophic cardiomyopathy, we performed echocardiogra-
phy on the DMTG mouse hearts and force-Ca2+ measurements on skinned papillary 
muscle fiber bundles. Results show improved systolic function with increases in 
ejection fraction and fractional shortening when compared with α-Tpm E180G and 
control littermates (Table 1) [27]. In addition, diastolic function is significantly 
improved in the DMTG animals, which demonstrates the rescue from the extreme 
diastolic dysfunction seen in the HCM α-Tpm E180G mice. We measured myofila-
ment Ca2+ sensitivity in the DMTG mice to determine whether this parameter could 
also contribute to the improved cardiac function. Myofilaments from the DMTG 
mice show a significant decrease in Ca2+ sensitivity when compared with the HCM 
α-Tpm E180G measurements as indicated by a lower pCa50 value; the maximum 
tension and Hill coefficient are not significantly different among control, HCM 
α-Tpm E180G, and DMTG myofilaments. The conclusion of these results demon-
strates that decreased phosphorylation of Tpm can morphologically and physiologi-
cally rescue the pathological phenotype associated with HCM.
To examine potential signaling mechanisms that may be operative in DMTG 
animals that might play a role in the rescue of the HCM phenotype, we assayed gene 
expression of cardiomyopathy markers and Ca2+-handling proteins. Results show 
that β-myosin heavy chain (β-MHC), BNP, and ANP exhibit significantly lower 
levels than those found in the HCM α-Tpm E180G hearts; the levels in the DMTG 
animals are similar to control mice [27]. Results show there are no differences in 
SERCA2a levels among control, α-Tpm E180G, and DMTG animals, but there is an 
increase in total PLN phosphorylation in the DMTG mice. It is possible that this 
Figure 5. 
A. Histological studies of NTG, Tm180, and DMTG hearts at 3 months of age stained with H&E, Masson’s 
trichrome, and wheat germ agglutinin (WGA). Images were taken at 40×, and scale bars indicate 50 μm. 
B. Cardiomyocyte cross-sectional area measurements (n = 6). C. Heart weight-to-body weight (HW:BW) ratios 
at 3 months of age (n = 6). Error bars represent S.E. [27].
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increase in PLN phosphorylation releases the inhibition on SERCA2a, thus stimulat-
ing Ca2+ resequestration into the sarcoplasmic reticulum to help rescue the HCM 
phenotype in the DMTG hearts. Other studies show that modification in contractile 
protein phosphorylation can improve sarcomeric and cardiac function. Deletion of 
the amino-terminal cardiac troponin I (TnI) domain improves cardiac contractility 
in aged mice, and cardiac function can be improved in restrictive cardiomyopathy 
mice when crossed with a TG mouse expressing a truncated amino-terminal TnI 
molecule [46, 47]. Also, phosphorylation of myosin light chain kinase can normal-
ize increased Ca2+ sensitivity in an HCM model of regulatory light chain [48]. The 
molecular mechanism(s) that is activated by decreasing Tpm phosphorylation to 
improve cardiac function is unknown; however, studies suggest that the MEK1-
ERK1/2 pathway may be involved in reversing the α-Tpm E180G hypertrophy [49, 
50]. Another signaling pathway that might be involved in preventing the disease 
phenotype in the DMTG mice involves protein phosphatase 2a and casein-kinse-
2-interacting protein (CKIP-1). The HCM Tpm E180G mice have increased levels 
of PP2a and casein kinase-2 [51, 52]. CKIP-1 and PP2a directly interact [53], which 
facilitates the binding of PP2a to HDAC4 to promote HDAC’s dephosphorylation. 
Dephosphorylation of HDAC suppresses cardiac hypertrophy and the fetal cardiac 
gene program [53]. If decreased Tpm phosphorylation leads to increased levels 
of CKIP-1 expression, then this signaling pathway may be activated in the rescue 
DMTG mice.
6. Conclusions
As cited above, these studies collectively demonstrate a significant biological 
and physiological role for Tpm phosphorylation under both normal and cardiomyo-
pathic conditions. The penultimate Tpm amino acid, serine residue 283, is located 
in a carboxyl region that is associated with multiple protein interactions: dimers 
between C-terminal Tpm molecules, C-terminal Tpm overlapping with N-terminal 
Tpm, and C-terminal Tpm binding with N-terminal troponin T. These multiple 
protein-protein interacting regions regulate myofilament function and cardiac 
performance, and are dramatically altered with changes in Tpm phosphorylation. 
Understanding the significance of developmental and disease associated changes 
that occur in Tpm phosphorylation is an area for future exploration. In addition, 
determining whether changes in Tpm phosphorylation are causative or a conse-
quence of HCM is vital to developing therapeutic strategies for cardiovascular 
disease. An area of future investigation is to identify drug targets for the various 
kinases that phosphorylate Tpm and their downstream signaling factors so as to 
potentially treat various cardiomyopathic conditions.
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